Physician profile
Joseph Patrick Forester
NPI 1972520658
$719,043.88
in general payments reported to CMS, 2019-2025
28 companies · $109K in 2025
The $109K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115K · 2020: $63K · 2021: $87K · 2022: $121K · 2023: $92K · 2024: $131K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $278K · Travel and Lodging: $41K · Food and Beverage: $12K · Consulting Fee: $2,558 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $277,535.00 |
| Travel and Lodging | $40,806.95 |
| Food and Beverage | $11,865.75 |
| Consulting Fee | $2,557.50 |
| Education | $219.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $601,446.24 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Merck Sharp & Dohme LLC | $63,966.62 | 2019-2025 | Capvaxive |
| Genentech USA, INC. | $19,887.19 | 2019-2025 | Xolair, Actemra |
| Amgen INC. | $11,450.49 | 2022-2025 | Tezspire, Tavneos |
| Ars Pharmaceuticals Operations, INC. | $10,798.41 | 2025 | Neffy |
| Pfizer INC. | $6,200.31 | 2020-2022 | |
| Genzyme Corporation | $2,692.44 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $910.48 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $342.10 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $269.01 | 2024-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $210.20 | 2025 | |
| Sanofi-Aventis U.S. LLC | $122.98 | 2021-2024 | |
| Blueprint Medicines Corporation | $108.41 | 2024-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $101.62 | 2024-2025 | Cuvitru, Takhzyro |
| Gc Biopharma USA, INC. | $91.26 | 2025 | Alyglo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $59.47 | 2025 | Nemluvio |
| Insmed, INC. | $56.99 | 2025 | Arikayce |
| Cycle Pharmaceuticals INC | $53.62 | 2025 | Sajazir |
| Grifols USA, LLC | $53.26 | 2024-2025 | Xembify |
| Janssen Biotech, INC. | $51.80 | 2024 | Tremfya |
| Hikma Pharmaceuticals USA | $31.52 | 2025 | Ryaltris |
| Organon LLC | $29.10 | 2025 | Vtama |
| Octapharma USA, INC. | $23.08 | 2025 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $19.81 | 2024 | Cimzia |
| Melinta Therapeutics, LLC | $19.65 | 2023 | Kimyrsa, Rezzayo |
| Scilex Pharmaceuticals INC. | $18.26 | 2024 | |
| Alk-Abello, INC | $16.03 | 2020 | |
| Organogenesis INC. | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Forester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.